• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by BioCardia Inc.

    9/6/24 7:45:48 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BCDA alert in real time by email
    SC 13G 1 ea0213856-13gintra_bio.htm SCHEDULE 13G

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No.    )*

     

    BioCardia, Inc.

     

    (Name of Issuer)

     

    Common stock, par value $0.001 per share

     

    (Title of Class of Securities)

     

    09060U6006

     

    (CUSIP Number)

     

    August 29, 2024

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    a.☐ Rule 13d-1(b)
    b.☒ Rule 13d-1(c)
    c.☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    Page 1 of 7

     

    CUSIP No. 09060U6006

     

    1. Names of Reporting Persons.

    Mitchell P. Kopin
    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐
    (b)
    ☐
    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

     

    United States of America
    Number of
    Shares Beneficially
    Owned by Each
    Reporting
    Person With:
    5. 

    Sole Voting Power

     

    0
    6.

    Shared Voting Power

     

    185,689
    7.

    Sole Dispositive Power

     

    0
    8.

    Shared Dispositive Power

     

    185,689
    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

     

    185,689 (see Item 4)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐

     

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

     

    4.99% (see Item 4)

    12. Type of Reporting Person (See Instructions)

    IN; HC

     

    Page 2 of 7

     

    CUSIP No. 09060U6006

     

    1. Names of Reporting Persons.

    Daniel B. Asher
    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐
    (b)
    ☐
    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

     

    United States of America
    Number of
    Shares Beneficially
    Owned by Each
    Reporting
    Person With:
    5. 

    Sole Voting Power

     

    0
    6.

    Shared Voting Power

     

    185,689
    7.

    Sole Dispositive Power

     

    0
    8.

    Shared Dispositive Power

     

    185,689
    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

     

    185,689 (see Item 4)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐

     

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

     

    4.99% (see Item 4)

    12. Type of Reporting Person (See Instructions)

    IN; HC

     

    Page 3 of 7

     

    CUSIP No. 09060U6006

     

    1. Names of Reporting Persons.

    Intracoastal Capital LLC
    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐
    (b)
    ☐
    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

     

    Delaware
    Number of
    Shares Beneficially
    Owned by Each
    Reporting
    Person With:
    5. 

    Sole Voting Power

     

    0
    6.

    Shared Voting Power

     

    185,689
    7.

    Sole Dispositive Power

     

    0
    8.

    Shared Dispositive Power

     

    185,689
    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

     

    185,689 (see Item 4)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐

     

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

     

    4.99% (see Item 4)

    12. Type of Reporting Person (See Instructions)

    OO

     

    Page 4 of 7

     

    Item 1.

     

    (a) Name of Issuer

     

    BioCardia, Inc. (the “Issuer”)

     

    (b) Address of Issuer’s Principal Executive Offices

     

    320 Soquel Way

    Sunnyvale, California 94085

     

    Item 2.

     

    (a) Name of Person Filing

     

    (b) Address of Principal Business Office or, if none, Residence

     

    (c) Citizenship

     

    This Schedule 13G is being filed on behalf of (i) Mitchell P. Kopin, an individual who is a citizen of the United States of America (“Mr. Kopin”), (ii) Daniel B. Asher, an individual who is a citizen of the United States of America (“Mr. Asher”) and (iii) Intracoastal Capital LLC, a Delaware limited liability company (“Intracoastal” and together with Mr. Kopin and Mr. Asher, collectively the “Reporting Persons”).

     

    The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 1, pursuant to which the Reporting Persons have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended.

     

    The principal business office of Mr. Kopin and Intracoastal is 245 Palm Trail, Delray Beach, Florida 33483.

     

    The principal business office of Mr. Asher is 111 W. Jackson Boulevard, Suite 2000, Chicago, Illinois 60604.

     

    (d) Title of Class of Securities

     

    Common stock, par value $0.001 per share, of the Issuer (the “Common Stock”).

     

    (e) CUSIP Number

     

    09060U6006

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

    Item 4. Ownership.

     

    (a) and (b):

     

    (i) Immediately following the execution of the Securities Purchase Agreement with the Issuer on August 29, 2024 (the “SPA”) (as disclosed in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on September 3, 2024), each of the Reporting Persons may have been deemed to have beneficial ownership of 235,724 shares of Common Stock, which consisted of (i) 230,000 shares of Common Stoc to be issued to Intracoastal at the closing of the transaction contemplated by the SPA and (ii) 5,724 shares of Common Stock issuable upon exercise of a warrant to be issued to Intracoastal at the closing of the transaction contemplated by the SPA (“Intracoastal Warrant 1”), and all such shares of Common Stock in the aggregate represent beneficial ownership of approximately 9.99% of the Common Stock, based on (1) 2,123,876 shares of Common Stock outstanding as of July 31, 2024 as reported by the Issuer, plus (2) 230,000 shares of Common Stoc to be issued to Intracoastal at the closing of the transaction contemplated by the SPA and (3) 5,724 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1. The foregoing excludes (I) 27,953 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1 because Intracoastal Warrant 1 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 1 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 9.99% of the Common Stock and (II) 263,677 shares of Common Stock issuable upon exercise of a second warrant to be issued to Intracoastal at the closing of the transaction contemplated by the SPA (“Intracoastal Warrant 2”) because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock. Without such blocker provisions, each of the Reporting Persons may have been deemed to have beneficial ownership of 527,354 shares of Common Stock.

     

    Page 5 of 7

     

    (ii) As of the close of business on September 6, 2024, each of the Reporting Persons may have been deemed to have beneficial ownership of 185,689 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2, and all such shares of Common Stock in the aggregate represent beneficial ownership of approximately 4.99% of the Common Stock, based on (1) 2,123,876 shares of Common Stock outstanding as of July 31, 2024 as reported by the Issuer, plus (2) 1,377,990 shares of Common Stock issued at the closing of the transaction contemplated by the SPA, (3) 33,677 shares of Common Stock issued to Intracoastal upon exercise of Intracoastal Warrant 1 and (4) 185,689 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2. The foregoing excludes 77,988 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2 because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock. Without such blocker provision, each of the Reporting Persons may have been deemed to have beneficial ownership of 263,677 shares of Common Stock.

     

    (c) Number of shares as to which each Reporting Person has:

     

    (i)Sole power to vote or to direct the vote:            0             .

     

    (ii)Shared power to vote or to direct the vote:            185,689             .

     

    (iii)Sole power to dispose or to direct the disposition of            0            .

     

    (iv)Shared power to dispose or to direct the disposition of            185,689            .

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒.

      

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10. Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

    Page 6 of 7

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: September 6, 2024

     

      /s/ Mitchell P. Kopin
      Mitchell P. Kopin
       
      /s/ Daniel B. Asher
      Daniel B. Asher
       
      Intracoastal Capital LLC
       
      By: /s/ Mitchell P. Kopin
        Mitchell P. Kopin, Manager

     

    Page 7 of 7

     

    Get the next $BCDA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BCDA

    DatePrice TargetRatingAnalyst
    12/20/2021$9.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BCDA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025

      SUNNYVALE, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that BioCardia's CEO, Peter Altman, Ph.D., will participate in a fireside chat at the Alliance Global Partners Virtual Healthcare Company Showcase hosted by Jim Molloy, Managing Director, Equity Research Biotechnology & Specialty Pharmaceuticals at A.G.P., on May 21, 2025. Dr. Altman will share recent business developments on the Company's therapeutic development pipeline with a focus on its lead CardiAMP autologous cell therapy for the treatment of ischemic heart failure. Fire

      5/21/25 8:30:00 AM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCardia Reports First Quarter 2025 Business Highlights and Financial Results

      SUNNYVALE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the first quarter of 2025 and filed its quarterly report on Form 10-Q for the three months ended March 31, 2025 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management's formal remarks, there will be a question-and-answer session. Recent Business Highlights CardiAMP® autologous cell therapy in ischemic heart failure of reduced ejection fra

      5/14/25 4:05:00 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025

      SUNNYVALE, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three months ended March 31, 2025 by conference call on Wednesday, May 14, 2025 at 4:30 PM EDT. Following management's formal remarks, there will be a question-and-answer session. Participants can register for the conference by navigating to https://dpregister.com/sreg/10199950/ff25def0f6.   Please note that registered participants will receive their dial-in number upon registration. For those who have

      5/9/25 4:28:08 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. initiated coverage on BioCardia with a new price target

      HC Wainwright & Co. initiated coverage of BioCardia with a rating of Buy and set a new price target of $9.00

      12/20/21 6:05:04 AM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCardia downgraded by Dawson James

      Dawson James downgraded BioCardia from Buy to Neutral

      4/16/21 7:22:02 AM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCDA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Altman Peter bought $221 worth of shares (100 units at $2.21), increasing direct ownership by 0.07% to 141,766 units (SEC Form 4)

      4 - BioCardia, Inc. (0000925741) (Issuer)

      5/30/25 8:55:15 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Altman Peter bought $4,651 worth of shares (2,300 units at $2.02), increasing direct ownership by 2% to 141,666 units (SEC Form 4)

      4 - BioCardia, Inc. (0000925741) (Issuer)

      5/22/25 6:45:25 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Altman Peter bought $1,028 worth of shares (400 units at $2.57), increasing direct ownership by 0.29% to 139,366 units (SEC Form 4)

      4 - BioCardia, Inc. (0000925741) (Issuer)

      5/16/25 5:31:00 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $BCDA
    SEC Filings

    See more

    $BCDA
    Financials

    Live finance-specific insights

    See more

    $BCDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • President and CEO Altman Peter bought $221 worth of shares (100 units at $2.21), increasing direct ownership by 0.07% to 141,766 units (SEC Form 4)

      4 - BioCardia, Inc. (0000925741) (Issuer)

      5/30/25 8:55:15 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Altman Peter bought $4,651 worth of shares (2,300 units at $2.02), increasing direct ownership by 2% to 141,666 units (SEC Form 4)

      4 - BioCardia, Inc. (0000925741) (Issuer)

      5/22/25 6:45:25 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Altman Peter bought $1,028 worth of shares (400 units at $2.57), increasing direct ownership by 0.29% to 139,366 units (SEC Form 4)

      4 - BioCardia, Inc. (0000925741) (Issuer)

      5/16/25 5:31:00 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SCHEDULE 13D filed by BioCardia Inc.

      SCHEDULE 13D - BioCardia, Inc. (0000925741) (Subject)

      5/22/25 6:18:07 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCardia Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - BioCardia, Inc. (0000925741) (Filer)

      5/14/25 4:09:25 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by BioCardia Inc.

      10-Q - BioCardia, Inc. (0000925741) (Filer)

      5/14/25 4:05:54 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCardia Reports First Quarter 2025 Business Highlights and Financial Results

      SUNNYVALE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the first quarter of 2025 and filed its quarterly report on Form 10-Q for the three months ended March 31, 2025 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management's formal remarks, there will be a question-and-answer session. Recent Business Highlights CardiAMP® autologous cell therapy in ischemic heart failure of reduced ejection fra

      5/14/25 4:05:00 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025

      SUNNYVALE, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three months ended March 31, 2025 by conference call on Wednesday, May 14, 2025 at 4:30 PM EDT. Following management's formal remarks, there will be a question-and-answer session. Participants can register for the conference by navigating to https://dpregister.com/sreg/10199950/ff25def0f6.   Please note that registered participants will receive their dial-in number upon registration. For those who have

      5/9/25 4:28:08 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioCardia's Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today

      SUNNYVALE, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today clarifies that two-year CardiAMP-HF results will be addressed in a conference call scheduled for today, Monday, March 31, 2025 at 4:30pm EDT. The press release earlier this morning incorrectly noted the call would be held at 4:30pm PDT. To access the call today:Participants can register for the conference by navigating to https://dpregister.com/sreg/10194429/fdf5f0e427. Please note that registered participants will receive their dial-in number upon registration. For those who have no

      3/31/25 1:39:56 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by BioCardia Inc.

      SC 13G - BioCardia, Inc. (0000925741) (Subject)

      9/6/24 7:45:48 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by BioCardia Inc. (Amendment)

      SC 13D/A - BioCardia, Inc. (0000925741) (Subject)

      4/5/24 4:13:08 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by BioCardia Inc. (Amendment)

      SC 13D/A - BioCardia, Inc. (0000925741) (Subject)

      2/27/24 4:53:40 PM ET
      $BCDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care